Program
Quinidine
Also written as “AVP-786”, “Quinidine Sulfate” and “Quinidine sulfate tablets”.
Its studies are mostly in Psychomotor Agitation · Schizophrenia · Dementia · Disruptive, Impulse Control, and Conduct Disorders, led by 4 companies.
Drug pageQuinidine: every studyAll 23 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Otsukaits history only | 130 open or running | phase 3since May 11, 2015 | Jun 23, 2014 | none ahead |
| Boehringer Ingelheimits history only | 20 open or running | phase 1since Jun 20, 2014 | Jun 20, 2014 | none ahead |
| Bristol-Myers Squibbits history only | 10 open or running | phase 1since Jun 25, 2024 | Jun 25, 2024 | none ahead |
| Trevi Therapeuticsits history only | 11 open or running | phase 1since Nov 12, 2026 | Nov 12, 2026 | Nov 30, 2026phase 1 · NCT07946575 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 20, 2014First studies: 2 phase 1 studies in HealthyNew to Boehringer IngelheimBoehringer Ingelheim · NCT02171624, NCT02171546
- Jun 23, 2014Otsuka’s first studies: 2 phase 1 studiesNew to OtsukaOtsuka · NCT02174835, NCT02174822
- Jan 8, 2015Phase 1 study in Healthy VolunteerOtsuka · NCT02336347 · 62 enrolled · United States
- Feb 26, 2015Phase 1 study in HealthyOtsuka · NCT02402595 · 24 enrolled · United States
- May 11, 20152 phase 3 studiesOtsuka · NCT02446132, NCT02442765
- Jun 18, 2015Phase 2 study in SchizophreniaOtsuka · NCT02477670 · 145 enrolled · United States
- Aug 11, 2015Phase 2 study in Disinhibition SyndromeOtsuka · NCT02534038 · 1 enrolled · United States
- Jan 3, 2018Phase 3 study in Psychomotor AgitationOtsuka · NCT03393520 · 601 enrolled · United States, Australia, Bulgaria and more
- Jan 19, 2018Phase 2 study in Disruptive, Impulse Control, and Conduct DisordersOtsuka · NCT03420222 · 10 enrolled · United States
- Mar 19, 2019Phase 3 study in SchizophreniaOtsuka · NCT03896945 · 136 enrolled · United States, Bulgaria, Poland and more
- May 26, 2020Phase 3 study in Psychomotor AgitationOtsuka · NCT04408755 · 184 enrolled · United States, Bulgaria, Denmark and more
- Jul 6, 2020Phase 3 study in Psychomotor AgitationOtsuka · NCT04464564 · 241 enrolled · United States, Belgium, Canada and more
- Jun 25, 2024Bristol-Myers Squibb’s first study: phase 1 study in Healthy VolunteersNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT06493409 · 32 enrolled · United States
- Nov 12, 2026Trevi Therapeutics’ first study: phase 1 study in Healthy ParticipantsNew to Trevi TherapeuticsTrevi Therapeutics · NCT07946575 · 30 planned · United States
Ahead
- Nov 30, 2026Primary completion: phase 1 study in Healthy ParticipantsTrevi Therapeutics · NCT07946575
TargetBeta
“Sodium channel alpha subunit blocker; Sodium channel alpha subunit blocker”ChEMBL 37, by rule
Other programs on the same 10 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Lidocainerule | Keenova Therapeutics | phase 4 | 63 |
| Lamotriginerule | GlaxoSmithKline | phase 4 | 61 |
| Carbamazepinerule | grin-therapeutics-inc | phase 4 | 21 |
| Dronedaronerule | Sanofi | phase 4 | 18 |
| chloroprocainerule | sintetica-sa | phase 4 | 8 |
| Riluzolerule | Sanofi | phase 4 | 6 |
| Prilocainerule | Haisco Pharmaceutical Group | phase 4 | 2 |
| Carticainerule | Laboratoires Thea | phase 4 | 1 |
| Ropivacainerule | painreform-ltd | phase 3 | 17 |
| Phenytoinrule | Viatris | phase 3 | 10 |
| rufinamiderule | Eisai | phase 3 | 7 |
Studies
All 17 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07946575Healthy Participants · United States | 1 | Recruiting | Trevi Therapeutics | Nov 30, 2026 | 30 |
| NCT06493409Healthy Volunteers · United States | 1 | Completed | Bristol-Myers Squibb | Dec 7, 2024 | 32 |
| NCT04464564Psychomotor Agitation · United States, Belgium, Canada and more | 3 | Terminated | Otsuka | Jun 28, 2024 | 241 |
| NCT04408755Psychomotor Agitation · United States, Bulgaria, Denmark and more | 3 | Terminated | Otsuka | Jun 27, 2024 | 184 |
| NCT03896945Schizophrenia · United States, Bulgaria, Poland and more | 3 | Terminated | Otsuka | May 23, 2023 | 136 |
| NCT03420222Disruptive, Impulse Control, and Conduct Disorders · United States | 2 | Terminated | Otsuka | Dec 28, 2018 | 10 |
| NCT03393520Psychomotor Agitation · United States, Australia, Bulgaria and more | 3 | Completed | Otsuka | Nov 17, 2023 | 601 |
| NCT02534038Disinhibition Syndrome · United States | 2 | Terminated | Otsuka | Oct 3, 2017 | 1 |
| NCT02477670Schizophrenia · United States | 2 | Completed | Otsuka | Jul 21, 2017 | 145 |
| NCT02446132Agitation in Patients With Dementia of the Alzheimer's Type · United States, Bulgaria, Canada and more | 3 | Terminated | Otsuka | Sep 6, 2024 | 1,197 |
| NCT02442765Psychomotor Agitation · United States, Estonia, Germany and more | 3 | Completed | Otsuka | Jan 30, 2019 | 387 |
| NCT02402595Healthy · United States | 1 | Completed | Otsuka | Jul 1, 2015 | 24 |
| NCT02336347Healthy Volunteer · United States | 1 | Completed | Otsuka | Sep 1, 2014 | 62 |
| NCT02174835Healthy · Australia | 1 | Completed | Otsuka | Nov 1, 2013 | 56 |
| NCT02174822Drug-drug Interaction · Australia | 1 | Completed | Otsuka | Mar 2014 | 56 |
| NCT02171624Healthy | 1 | Completed | Boehringer Ingelheim | Apr 2009 | 42 |
| NCT02171546Healthy | 1 | Terminated | Boehringer Ingelheim | Jan 2008 | 42 |
How it is read
Names in the registry
- “AVP-786”, 13 entries
- “Quinidine Sulfate”, 1 entry
- “Quinidine”, 1 entry
- “Quinidine sulfate tablets”, 1 entry
- “quinidine”, 1 entry
Conditions, from the studies’ own filings
- Psychomotor Agitation, 3 studies
- Schizophrenia, 2 studies
- Dementia, 2 studies
- Disruptive, Impulse Control, and Conduct Disorders, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.